AZN•benzinga•
AstraZeneca Doses First Patient In DESTINY-Endometrial01 Phase 3 Trial Evlauating ENHERTU In Combination With Rilvegostomig Or Pembrolizumab Versus Platinum-Based Chemotherapy In Combination With Pembrolizumab As First-Line Therapy In Patients With HER2 E
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on June 9, 2025 by benzinga